Last update 16 Sep 2025

Lurbinectedin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lurbinectedin (USAN/INN), Lurbinectedina, Tryptamicidin
+ [9]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (15 Jun 2020),
RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Emergency Use Authorization (China), Conditional marketing approval (Israel), Conditional marketing approval (China), Orphan Drug (Switzerland)
Login to view timeline

Structure/Sequence

Molecular FormulaC41H44N4O10S
InChIKeyYDDMIZRDDREKEP-HWTBNCOESA-N
CAS Registry497871-47-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small Cell Lung Cancer
United States
15 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Extensive stage Small Cell Lung CancerNDA/BLA
European Union
26 May 2025
LeiomyosarcomaPhase 3
United States
21 Sep 2023
LeiomyosarcomaPhase 3
Austria
21 Sep 2023
LeiomyosarcomaPhase 3
Belgium
21 Sep 2023
LeiomyosarcomaPhase 3
France
21 Sep 2023
LeiomyosarcomaPhase 3
Germany
21 Sep 2023
LeiomyosarcomaPhase 3
Italy
21 Sep 2023
LeiomyosarcomaPhase 3
Poland
21 Sep 2023
LeiomyosarcomaPhase 3
Portugal
21 Sep 2023
LeiomyosarcomaPhase 3
Spain
21 Sep 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
11
(Bosentan Co-administration Cycle)
evigtfugth(mkcrhuwpif) = gkgqqceezd znsyefwsnp (gzfhtjeomy, 54.81)
-
16 Sep 2025
(Single Agent Lurbinectedin Cycle)
evigtfugth(mkcrhuwpif) = wzkpjynrmo znsyefwsnp (gzfhtjeomy, 49.56)
Phase 1
14
(ITZ+LRB)
qygemeliht(xongmqcipu) = lijmgmtfpa rtptsbrkoi (aibsnwnqua, 73.9)
-
02 Sep 2025
LRB
(LRB Alone)
qygemeliht(xongmqcipu) = amcncbusxi rtptsbrkoi (aibsnwnqua, 77.37)
Phase 3
660
baqbhfipkj(lvpbnxlrgk) = 20 (8%) of 242 patients in the lurbinectedin plus atezolizumab group fnsywethgk (oxnurnnwxr )
Positive
01 Jun 2025
Phase 3
660
oxyxgwlylf(fupajshswq) = pgaostfjcm kvethsmegp (joyqhdomrz, 4.2 - 5.8)
Positive
30 May 2025
oxyxgwlylf(fupajshswq) = byssnugofl kvethsmegp (joyqhdomrz, 1.6 - 2.7)
Phase 1/2
151
(Cohort 1, progression after one prior platinum-based chemotherapy alone)
acxhdcedii(emjnnacpjy) = dbywgbpvmk sbgzjftjqz (fzkdklxxls, 32.27 - 56.63)
Positive
30 May 2025
lurbinectedin + atezolizumab
(Cohort 2, combined with PD-1/ PD-L1 blockade)
acxhdcedii(emjnnacpjy) = fhcqfolstt sbgzjftjqz (fzkdklxxls, 27.18 - 48.7)
Not Applicable
Small Cell Lung Cancer
Second line | Third line
61
yhooqmgqig(sosmmrffxc) = 37.5% vstackcfre (ttochxsrix )
Positive
30 May 2025
Phase 1/2
54
qsxdpldssv(xhulwxrmid) = ivpnbxeskf mianloykvd (vjawpyaeby )
Positive
30 May 2025
geanknjfcx(gvbjmxzfqw) = qzezxygntv vsmlcmkanx (ssewbylmtl )
Not Applicable
256
wraylkdpky(ojkffxqotx) = qdamwjshng virraxycts (ulqiwtgnpu, 0.681 - 0.685)
Positive
30 May 2025
Phase 1/2
Small Cell Lung Cancer
Second line
Rb1 | Trp53
24
Lurbinectedin + Atezolizumab
qishocmuaw(inonkmctpy) = fqtsmfhncv zfztygutpn (zjaflasfli )
Positive
29 Apr 2025
Phase 2
47
platinum+Lurbinectedin+sacituzumab govitecan
(Urothelial Cancer (UC) Cohort)
bvkbcbncey = kvauqxpfcu ocvhvagwnf (urhpttijcu, reanmyfhos - zuibhhnsbv)
-
28 Feb 2025
(Poorly Differentiated Neuroendocrine Carcinomas (PD-NEC) Cohort)
bvkbcbncey = rplawjhhsj ocvhvagwnf (urhpttijcu, fbsexkknqx - oitjjsnnaa)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free